Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2916 - Phase I dose escalation study with expansion cohort of the addition of Nab-Paclitaxel (nab-P) to capecitabine and oxaliplatin (CAPOX) as first line treatment of advanced esophagogastric adenocarcinoma (EGAC) (ACTION study).

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Oesophageal Cancer;  Gastric Cancer

Presenters

Sandor Schokker

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

S. Schokker1, D.J. Van Zoen2, S.O. Van der Woude1, S.L. Meijer3, R.A..A. Mathot4, M.F. Bijlsma5, M.G.H. Van Oijen2, C.J.A. Punt6, H.W.M. van Laarhoven7

Author affiliations

  • 1 Cancer Center Amsterdam, Laboratory Of Experimental Oncology And Radiobiology, Department Of Medical Oncology, Academic Medical Center Amsterdam, 1105AZ - Amsterdam/NL
  • 2 Department Of Medical Oncology, Academic Medical Center Amsterdam, 1105AZ - Amsterdam/NL
  • 3 Department Of Pathology, Academic Medical Center (AMC)Academic Medical Center Amsterdam, 1105AZ - Amsterdam/NL
  • 4 Department Of Clinical Pharmacology, Academic Medical Center Amsterdam, 1105AZ - Amsterdam/NL
  • 5 Cancer Center Amsterdam, Laboratory Of Experimental Oncology And Radiobiology, Academic Medical Center Amsterdam, 1105AZ - Amsterdam/NL
  • 6 Cancer Center Amsterdam, Department Of Medical Oncology, Academic Medical Center Amsterdam, 1100 DD - Amsterdam/NL
  • 7 Cancer Center Amsterdam, Laboratory Of Experimental Oncology And Radiobiology, Department Of Medical Oncology, Academic Medical Center Amsterdam, 1100 DD - Amsterdam/NL
More

Resources

Abstract 2916

Background

The prognosis of advanced EGAC remains poor. Triplets containing taxanes show a survival benefit but at the cost of increased toxicity. Given the favorable toxicity profile of nab-P compared to conventional taxanes we conducted a phase 1 dose escalation study to find the maximum tolerated and recommended phase 2 dose (MTD/RP2D) of the addition of nab-P to CAPOX.

Methods

Patients (pts) with metastatic or non-resectable EGAC received oxaliplatin 65 mg/m2 day 1 and 8 and capecitabine 1000 mg/m2 bid day 1-14 in a 21 day cycle, with nab-P day 1 and 8 at 4 dose levels (DL1 60, DL2 80, DL3 100 and DL4 120 mg/m2, respectively) in a standard 3 + 3 design, followed by an expansion cohort of 20 pts. Tumor response was assessed every 3 cycles (RECIST 1.1). Pts were treated until progressive disease (PD), unacceptable toxicity or a maximum of 6 cycles after which capecitabine monotherapy was continued. Ox and nab-P were reintroduced if PD occurred after more than 3 months.

Results

We enrolled 26 pts (median age 63; 18 had esophageal cancer and 8 gastric cancer). Ten pts had received prior curative treatment. At DL1 and DL2 no dose limiting toxicity (DLT) occurred. At DL3 2 DLT’s occurred (diarrhea and dehydration due to vomiting/diarrhea). MTD was established at 80 mg/m2 and chosen for evaluation in the expansion cohort. However, because of diarrhea grade 3 in 5/12 pts (42%) in the course of treatment the nab-P dose was reduced to 60 mg/m2. Grade 3/4 toxicity of all pts treated at this DL was nausea (18%), diarrhea, vomiting, anorexia and elevated GGT (all 9%). Notable grade 1/2 toxicities were neuropathy (82%), dysgeusia, diarrhea (both 64%), nausea (55%) and vomiting (45%). Best responses were PR (13 pts), SD (9 pts) and PD (2 pts). Median follow up is 9.1 months, 22 pts completed 6 cycles and 5 pts are still on treatment of whom 4 on capecitabine monotherapy. Median PFS is 8.0 months.

Conclusions

MTD of nab-P in combination with CAPOX is 80 mg/m2 and RP2D 60 mg/m2 in a 3-weekly schedule. Given the manageable toxicity at RP2D and promising efficacy, further evaluation of this regimen is warranted. Biomarker research is currently ongoing.

Clinical trial identification

EudraCT: 2014-001333-88 Release date: March 25th 2014

Legal entity responsible for the study

Academic Medical Center Amsterdam

Funding

Celgene

Disclosure

S. Schokker: Travel/accomodation funding from Roche R.A.A. Mathot: Consultant for Zeria LTD, has received unrestricted research funding from Shire, MSD and Roche, travel/accomodation funding from Shire M.F. Bijlsma: Unrestricted research funding from Celgene, travel/accommodation funding from Biouniversa M.G.H. Van Oijen: Unrestricted research grants from Amgen, Bayer, Lilly, Merck Serono, and Roche. C.J.A. Punt: Consultant for Nordic Pharma and Servier H.W.M. van Laarhoven: Consultant for Celgene, Lilly, and Nordic, unrestricted research funding from Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, and Roche All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.